Ollin Biosciences, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2026 | $156 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ollin Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).
SEC Form D · Jun 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2026
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Ollin Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jason Ehrlich | Executive officer | Jun 2026 |
| Alaa Halawa | Director | Jun 2026 |
| Cariad Chester | Director | Jun 2026 |
| Fred Cohen | Director | Jun 2026 |
| Jason Coloma | Director | Jun 2026 |
| Jason Ehrlich | Director | Jun 2026 |
| Paul Berns | Director | Jun 2026 |
| Travis Murdoch | Director | Jun 2026 |